The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial
Abstract
Background— Oxidized phospholipids (OxPL) are present within atherosclerotic plaques and bound by lipoprotein (a) [Lp(a)] in plasma. This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS). Methods and Results— OxLDL-E06 (OxPL content on apolipoprotein B-100 [apoB] detected by antibody E06), apoB-100 immune complexes (apoB-IC), OxLDL autoantibodies, and Lp(a) levels were measured in 2341 patients at baseline and after 16 weeks of treatment with atorvastatin 80 mg/d or placebo. The OxLDL-E06 and apoB-IC data are reported per apoB-100 particle (OxPL/apoB, IC/apoB) and as total levels on all apoB-100 particles (total apoB-OxPL and total apoB-IC [eg, OxPL/apoB or IC/apoB×apoB-100 levels]). Compared with baseline values, atorvastatin reduced apoB-100 (−33%), total apoB-OxPL (−29.7%), total apoB-IC IgG (−29.5%), and IgM (−25.7%) ( P <0.0001 for all), whereas no change or an increase was observed with placebo. When normalized per apoB-100, compared with placebo, atorvastatin increased OxPL/apoB (9.5% versus −3.9%, P <0.0001) and Lp(a) (8.8% versus −0.7%, ( P <0.0001). A strong correlation was noted between OxPL/apoB and Lp(a) ( R =0.85, P <0.0001), consistent with previous data that Lp(a) binds OxPL. Conclusions— After atorvastatin treatment, total OxPL on all apoB-100 particles was decreased. However, there was enrichment of OxPL on a smaller pool of apoB-100 particles, in parallel with similar increases in Lp(a), suggesting binding by Lp(a). These data support the hypothesis that atorvastatin promotes mobilization and clearance of proinflammatory OxPL, which may contribute to a reduction in ischemic events after ACS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies reported no or only a minor increase in lipoprotein (a) (Lp(a)) levels among patients treated with statins [33, 34].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [33]
In the citing paper
“Available evidence consistently demonstrates a TCand LDL-Clowering effect of β-glucan, a viscous fibre from oat and barley.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [186]
In the citing paper
“Foods enriched with these fibres or supplements are well tolerated, effective, and recommended for LDL-C lowering [186].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citationNissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,274
Crisby, M., Fredrikson, G. N., Shah, P. K., Yano, J., Zhu, J., & Nilsson, J. Å. (2001) · Circulation · doi:10.1161/01.cir.103.7.926 · Cited by 999
Ehara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 780
Binder, C. J., Hörkkö, S., Dewan, A. K., Chang, M.-K., Kieu, E., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., & Silverman, G. J. (2003) · Nature Medicine · doi:10.1038/nm876 · Cited by 735
Self-citation
Research works printed but not linked: 10
Cited by
Sorted by citations
Items 201–225 of 225
Lipids, Atherogenic Dyslipidemia, and Therapy
Levine, T. B., & Levine, A. B. (2012) · Wiley eBooks · doi:10.1002/9781118480045.ch13 · Cited by 1
van Tits, L. J., Graaf, J. D., & Stalenhoef, A. F. H. (2005) · Circulation · doi:10.1161/01.cir.0000164264.00913.6d · Cited by 1
Chakraborty, S. (2010) · ScholarWorks @ The University of New Orleans (The University of New Orleans)
Oxidized Low Density Lipoprotein, Statin Therapy and Carotid Stenosis
Skopelitis, E. E., Levisianou, D., Gialernios, T., & Kougialis, S. (2012) · InTech eBooks · doi:10.5772/25833
Medications for the treatment of acute coronary syndromes
Brieger, D. B. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.16.2843
Fundamentos del tratamiento farmacológico actual de la cardiopatía isquémica
Andrea, R., Bellera, N., Loma-Osorio, P., & Heras, M. (2006) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(06)74818-x
OLSSON, A. G., Schwartz, G. G., Ezekowitz, M. D., Ganz, P., Oliver, M. F., Waters, D. D., Zeiher, A. M., Sasiela, W. J., & Szarek, M. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(04)91221-1
Self-citationBellera, N., Loma-Osorio, P., & Heras, M. (2016)
Владиславович, Е. М. (2010) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2010-6-4-573-577
Carcinoma da bexiga num modelo animal experimental : efeito preventivo de uma estatina
Pinto, Â. F. F. (2009) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Diao, Y., Li, H., Li, H., Zhou, Y., Ma, Q., Wang, Y., & Li, D. (2015)
Sorrentino, M. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-502-6_10
Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease
Rosenson, R. S., & Stafforini, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00013-x
Schwartz, G. G., & Do, R. Q. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00039-6
Self-citationCui, J., Zhang, Y., Zhang, W., Li, D., Hong, Z., Zhao, L., Sun, J., Chen, Y., & Zhang, N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01218-2 · Cited by 1
Oxidized Low-Density Lipoprotein and Atherogenesis
Gibbs, B. T. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4288-1_12
Johnston, N. (2006) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Shiyovich, A., Berman, A. N., Besser, S. A., Biery, D. W., Cardoso, R. N., Divakaran, S., Singh, A., Huck, D. M., Weber, B., Plutzky, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751119
Myagmarsuren, M., Law, H. G., Zhang, W., Bang, H., Bishop, L. M., Shen, T., Fiehn, O., Petersen, K. S., Berglund, L., & Enkhmaa, B. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101032
Approches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff
Chemello, K. (2022) · theses.fr (ABES) · doi:10.70675/6f647f12za09bz494fzae02z9be71ebf2915
Chang, S.-H. (2010) · Spiral (Imperial College London) · doi:10.25560/11743
Metadata
- Authors
- Tsimikas, S., Witztum, J. L., Miller, E. R., Sasiela, W. J., Szarek, M., Olsson, A. G., & Schwartz, G. G.
- Affiliations
- Linköping University (SE)
- Corresponding author
- Tsimikas, Sotirios
- ORCID
- Venue
- Circulation
- Published
- 2004-09-14
- Volume
- 110
- Issue
- 11
- Pages
- 1406-1412
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2109629533
- Semantic Scholar
- 5d8d1d7bcae3432d2e03d42643169af12f5e5419
- Cited by
- 225
- References
- 45
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 15 · 2015: 13 · 2014: 10 · 2013: 10 · 2012: 9
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Donald W. Reynolds Foundation
- Pfizer
- National Heart, Lung, and Blood Institute (P50HL056989, HL-56989)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- atorvastatin, oxidized phospholipids, oxidized LDL, apolipoprotein B-100, immune complexes, lipoprotein(a), acute coronary syndrome, statin therapy, atherosclerosis, atherosclerotic plaque
- MeSH terms
- Atorvastatin, Aged, Angina, Unstable, Antigen-Antibody Complex, Apolipoproteins B, Autoantibodies, Double-Blind Method, Female, Heptanoic Acids, Humans, Immunoglobulin G, Immunoglobulin M, Lipoproteins, LDL, Male, Middle Aged, Myocardial Infarction, Oxidation-Reduction, Phospholipids, Pyrroles, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
